Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Liposarcoma × selinexor × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 15 Recurrence 7 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, T-Cell, Peripheral 3 Glioblastoma 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Sarcoma 2 Primary Myelofibrosis 2 Neoplasms 2 Melanoma 2 Lymphoma, T-Cell, Cutaneous 2 Carcinoma, Squamous Cell 2 Waldenstrom Macroglobulinemia 1 Uterine Neoplasms 1 Uterine Diseases 1 Uterine Cervical Neoplasms 1 Richter's Transformation 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neoplasms, Plasma Cell 1 Neoplasms by Site 1 Myeloproliferative Disorders 1 Lymphoma, Non-Hodgkin 1 Liposarcoma 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1

Interventions

Trabectedin 4 Doxorubicin 3 brigimadlin 2 belinostat 2 Fulvestrant 2 Dexamethasone 2 toripalimab 1 tanespimycin 1 soblidotin 1 siremadlin 1 selinexor 1 ridaforolimus 1 ribociclib 1 pembrolizumab 1 olaratumab 1 milademetan 1 enzalutamide 1 cemiplimab 1 atezolizumab 1 TTI-621 1 Sugars 1 Midazolam 1 Letrozole 1 Imatinib Mesylate 1 Histamine H2 Antagonists 1 Fluorouracil 1 Famotidine 1 Docetaxel 1 Dacarbazine 1 Clinical Trials, Phase II as Topic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡